Abstract

BackgroundRapid diagnostic test (RDT) is an important tool for parasite-based malaria diagnosis. High specificity of RDTs to distinguish an active Plasmodium falciparum infection from residual antigens from a previous infection is crucial in endemic areas where residents are repeatedly exposed to malaria. The efficiency of two RDTs based on histidine-rich protein 2 (HRP2) and lactate dehydrogenase (LDH) antigens were studied and compared with two microscopy techniques (Giemsa and acridine orange-stained blood smears) and real-time polymerase chain reaction (PCR) for assessment of initial clearance and detection of recurrent P. falciparum infections after artemisinin-based combination therapy (ACT) in a moderately high endemic area of rural Tanzania.MethodsIn this exploratory study 53 children < five years with uncomplicated P. falciparum malaria infection were followed up on nine occasions, i.e., day 1, 2, 3, 7, 14, 21, 28, 35 and 42, after initiation of artemether-lumefantrine treatment. At each visit capillary blood samples was collected for the HRP2 and LDH-based RDTs, Giemsa and acridine orange-stained blood smears for microscopy and real-time PCR. Assessment of clearance times and detection of recurrent P. falciparum infections were done for all diagnostic methods.ResultsThe median clearance times were 28 (range seven to >42) and seven (two to 14) days for HRP2 and LDH-based RDTs, two (one to seven) and two (one to 14) days for Giemsa and acridine orange-stained blood smear and two (one to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for HRP2 on day 14, reaching 87% on day 42, and ≥96% from day 14 to 42 for LDH. There was no significant correlation between parasite density at enrolment and duration of HRP2 positivity (r = 0.13, p = 0.34). Recurrent malaria infections occurred in ten (19%) children. The HRP2 and LDH-based RDTs did not detect eight and two of the recurrent infections, respectively.ConclusionThe LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for the choice of RDT devices in similar transmission settings for improved malaria case management.Trial registrationClinicaltrials.gov, NCT01843764

Highlights

  • Rapid diagnostic test (RDT) is an important tool for parasite-based malaria diagnosis

  • This is of particular concern in moderate/high transmission areas where false positive RDTs may frequently result in provision of anti-malarial treatment to patients who are not malaria infected

  • Study site and population This health facility-based study was conducted during the peak seasons for malaria transmission, in June to September 2009 and July to October 2010 at Mlandizi health centre, Kibaha district and during March to May 2011 in Fukayosi dispensary, Bagamoyo district, both located in Coast Region, Tanzania

Read more

Summary

Introduction

Rapid diagnostic test (RDT) is an important tool for parasite-based malaria diagnosis. Parasite-based Plasmodium falciparum diagnosis is generally recommended by the World Health Organization (WHO) to target artemisinin-based combination therapy (ACT) to patients with confirmed malaria infections [1]. This is important in order to prevent overuse of ACT, reduce costs, minimize development and spread of antimalarial drug resistance and to improve management of other causes of fever [2,3]. A concern with HRP2-based RDTs is the presence of residual antigenaemia resulting in persistent positive test results during several weeks after a successful treatment [5,6] This is of particular concern in moderate/high transmission areas where false positive RDTs may frequently result in provision of anti-malarial treatment to patients who are not malaria infected. This phenomenon may impair health workers trust in and adherence to RDT results [7,8]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call